Clariant is gearing up to unveil its latest innovations in healthcare at the much-anticipated CPHI India 2024 tradeshow, set to take place in Delhi NCR from November 26 to 28. This year’s showcase emphasizes the company’s “Made in India” offerings, underscoring Clariant’s commitment to blending global expertise with local manufacturing excellence to meet the demands of the evolving pharmaceutical landscape.

India’s role as a global pharmaceutical leader is undeniable, producing over half of the world’s vaccines and 40% of generic drugs. Recognizing this potential, Clariant has positioned its Bonthapally facility at the heart of its strategy, combining advanced production capabilities with rigorous global compliance standards.

According to Vaios Barlas, Global Head of Health Care at Clariant, the company’s approach is clear: “Our Made in India products are integral to improving drug formulation, delivery, and patient outcomes. At the same time, we’re committed to compliance with the highest industry standards.”

Excipients are a cornerstone of pharmaceutical innovation, enhancing the stability, bioavailability, and efficacy of active pharmaceutical ingredients (APIs). As the global market for excipients grows at an expected rate of 6-7% annually, driven by aging populations, increasing use of specialty drugs, and stricter regulations, Clariant is stepping up to meet these needs.

Its Bonthapally facility exemplifies this effort, producing ultra-pure excipients designed to meet the demands of parenteral formulations, biologics, and complex drug formulations. The facility’s adherence to FDA, EMA, and IPEC GMP guidelines ensures the highest standards of sterility and purity.

This year, Clariant’s portfolio highlights a series of innovative solutions addressing key pharmaceutical challenges. These include excipients tailored for sensitive APIs, such as VitiPure™ LEX Series and VitiPure Superior Series, which are optimized for parenteral formulations and biologics requiring exceptional purity and stability.

Another noteworthy product, VitiPure™ Meglumine LEX, has been developed to enhance the bioavailability of mildly acidic APIs, offering a low endotoxin solution ideal for sensitive applications. For solid oral and topical formulations, VitiPure™ HCO, a micronized hydrogenated castor oil, provides a reliable alternative for tablet lubrication and consistency in topical agents.

Clariant’s dedication to innovation extends beyond product development. The company’s advanced cleanroom facilities and nitrogen-purged steel packaging processes reflect its focus on maintaining the highest levels of sterility and product integrity. These advancements ensure not only efficacy but also safety, critical for sensitive applications in biologics, vaccines, and specialty drugs.

For Clariant, this isn’t just about meeting market demands—it’s about shaping the future of healthcare. Bhushan Thekedar, Head of Global Business Development, Health Care, emphasized the dual mission of addressing local needs while maintaining global standards.

“Our operations in India cater to the specialized needs of the regional market while adhering to the global benchmarks required by regulatory bodies. This dual approach positions us as a trusted partner in the pharmaceutical sector, supporting the development of biologics, injectables, and complex drug formulations.”

As the pharmaceutical industry faces growing challenges, Clariant’s commitment to innovation, sustainability, and local manufacturing ensures it remains a pivotal player in delivering high-quality healthcare solutions worldwide. Visitors to CPHI India 2024 will have the opportunity to experience firsthand how Clariant is transforming pharmaceutical formulations through its cutting-edge excipients and global expertise.